2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products
How did staff layoffs, inspection backlogs and unprecedented leadership turnover affect the ability of the FDA to approve new drugs in 2025? While it would be presumptuous to base conclusions solely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results